What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?

Maissaa Janbain; Steven Pipe

doi:10.1182/asheducation-2016.1.648

What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):648-649. doi: 10.1182/asheducation-2016.1.648.

Authors

Maissaa Janbain¹, Steven Pipe²

Affiliations

¹ Section of Hematology and Medical Oncology, Department of Internal Medicine, Tulane School of Medicine, New Orleans, LA.
² Division of Pediatric Hematology and Oncology, University of Michigan, Ann Arbor, MI.

Abstract

A 10-year-old boy presents with a history of severe hemophilia A and high-titer inhibitor that had failed high-dose immune tolerance induction (ITI) with a recombinant factor VIII (rFVIII) product and a plasma-derived FVIII product. You are asked by his mother whether he should be tried on ITI with an extended half-life product, in particular, consideration of a rFVIIIFc concentrate.

Publication types

Case Reports
Review

MeSH terms

Child
Factor VIII* / administration & dosage
Factor VIII* / pharmacokinetics
Half-Life
Hemophilia A / blood*
Hemophilia A / drug therapy*
Hemophilia A / immunology*
Humans
Immune Tolerance / drug effects*
Male

Substances

F8 protein, human
Factor VIII